Assessment of liver function with Dynamic Contrast-Enhanced MRI in patients scheduled for liver resection - a pilot study.

Assessment of liver function with Dynamic Contrast-Enhanced MRI in patients scheduled for liver resection - a pilot study. - DCE-MRI vs. 99m-Tc HBS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46928

Enrollment

Registered

2013-09-11

Start date

2014-12-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer liver metastasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patients diagnosed with one or more liver lesions who are scheduled for 99mTc-HBS * Visit 1 scheduled within preferably 7 but at most 14 days before or after 99mTc-HBS (with at least 4 hours between visits if scheduled on the same day) * Age *18 years * Signed informed consent obtained prior to any study-specific procedure

Exclusion criteria

Exclusion criteria: * General contraindications for MRI (such as pregnancy and claustrophobia) * Chronic renal insufficiency or eGFR

Design outcomes

Primary

Measure	Time frame
* DCE-MRI: maximum enhancement, time to peak, slope of enhancement, wash-out rate * Quantitative T1 mapping: T1 99mTc-HBS (performed as part of clinical work-up): liver uptake function	—

Secondary

Measure	Time frame
* Liver fat percentages (MR fat mapping) * Liver microperfusion (IVIM) * Histology results of the microscopic examination of the resected liver: * Degree of fibrosis and steatosis * Histology results of the microscopic examination of the liver biopsy of the future remnant liver: * Degree of fibrosis and steatosis	—

Countries

Netherlands

Outcome results